EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Luciano Nicosia, Gary J Spencer, Nigel Brooks, Fabio M R Amaral, Naseer J Basma, John A Chadwick, Bradley Revell, Bettina Wingelhofer, Alba Maiques-Diaz, Oliver Sinclair, Francesco Camera, Filippo Ciceri und 11 weitere

Cancer Cell · 2023-12 · 41 (12) · 2136-2153.e13

DOI: 10.1016/j.ccell.2023.11.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023-12. Verfasst von Luciano Nicosia und 22 weiteren Autor:innen. Beteiligte Einrichtung: Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK. Hauptthemen laut MEDLINE: Nuclear Proteins, Hematologic Neoplasms. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Blood Cancer UK, Leukaemia UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In myeloid leukemia cells, it promotes rapid eviction of EP300/CBP from an enhancer subset marked by strong MYB occupancy and high H3K27 acetylation, with downregulation of the subordinate oncogenic network and redistribution to sites close to differentiation genes. In myeloma cells, CCS1477 induces eviction of EP300/CBP from FGFR3, the target of the common (4; 14) translocation, with redistribution away from IRF4-occupied sites to TCF3/E2A-occupied sites. In a subset of patients with relapsed or refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in heavily pre-treated multiple myeloma. In vivo preclinical combination studies reveal synergistic responses to treatment with standard-of-care agents. Thus, CCS1477 exhibits encouraging preclinical and early-phase clinical activity by disrupting recruitment of EP300/CBP to enhancer networks occupied by critical transcription factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear ProteinsHematologic NeoplasmsHumansCell Line, TumorTranscription FactorsProtein DomainsE1A-Associated p300 Protein

Substanzen

Nuclear ProteinsTranscription FactorsEP300 protein, humanE1A-Associated p300 Protein

Autor:innen und Institutionen

  • Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
  • CellCentric Ltd., Cambridge CB10 1XL, UK.
  • Epigenetics of Haematopoiesis Group, The University of Manchester, Manchester M20 4BX, UK.
  • Western General Hospital, Edinburgh EH4 2XU, UK.
  • The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
  • Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow G12 0YN, UK.

Förderung

  • Cancer Research UK
  • Blood Cancer UK
  • Leukaemia UK

Zitieren

APA

Nicosia, L., Spencer, G. J., Brooks, N., Amaral, F. M. R., Basma, N. J., Chadwick, J. A., Revell, B., Wingelhofer, B., Maiques-Diaz, A., Sinclair, O., Camera, F., Ciceri, F., Wiseman, D. H., Pegg, N., West, W., Knurowski, T., Frese, K., Clegg, K., Campbell, V. L., …, & Somervaille, T. C. P. (2023). Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell, 41(12), 2136-2153.e13. https://doi.org/10.1016/j.ccell.2023.11.001

Vancouver

Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, et al. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell. 2023;41(12):2136-2153.e13. doi:10.1016/j.ccell.2023.11.001

BibTeX
@article{Nicosia2023,
  author = {Nicosia, Luciano and Spencer, Gary J and Brooks, Nigel and Amaral, Fabio M R and Basma, Naseer J and Chadwick, John A and Revell, Bradley and Wingelhofer, Bettina and Maiques-Diaz, Alba and Sinclair, Oliver and Camera, Francesco and Ciceri, Filippo and Wiseman, Daniel H and Pegg, Neil and West, Will and Knurowski, Tomasz and Frese, Kris and Clegg, Karen and Campbell, Victoria L and Cavet, James and Copland, Mhairi and Searle, Emma and Somervaille, Tim C P},
  title = {Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies},
  journal = {Cancer Cell},
  year = {2023},
  volume = {41},
  number = {12},
  pages = {2136--2153.e13},
  doi = {10.1016/j.ccell.2023.11.001}
}
Kostenlos starten →